Regulatory T Lymphocyte Inhibitor (Treg Inhibitor)

Regulatory T lymphocyte inhibitors encompass a range of molecules and therapeutic strategies designed to suppress the activity or function of regulatory T cells (Tregs). Tregs are a critical component of immune tolerance, preventing autoimmunity and modulating immune responses. By inhibiting Tregs, these therapies aim to enhance immune responses, particularly in cancer immunotherapy, where overcoming Treg-mediated immunosuppression can improve anti-tumor immunity. Approaches include antibodies targeting Treg surface markers, agonists/antagonists of Treg-associated receptors, and small molecules that disrupt Treg function or migration. A key challenge is to selectively inhibit Tregs without causing broad immune dysregulation and autoimmunity.

Other names

Treg InhibitorRegulatory T Cell BlockerImmunosuppression Inhibitor (Treg-specific)FOXP3+ Cell Inhibitor

Inhibits suppressive functions, migration, or survival signals of regulatory T lymphocytes; mechanisms vary depending on the specific inhibitor and can involve antibody-mediated depletion, receptor agonism/antagonism, or interference with signaling pathways.